4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $29.56.
A number of research firms recently commented on FDMT. Barclays decreased their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Chardan Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, July 3rd. The Goldman Sachs Group decreased their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday, July 12th.
Read Our Latest Stock Report on FDMT
4D Molecular Therapeutics Stock Performance
Shares of 4D Molecular Therapeutics stock traded up $0.21 on Friday, hitting $4.71. The company's stock had a trading volume of 340,477 shares, compared to its average volume of 734,192. 4D Molecular Therapeutics has a 1 year low of $2.24 and a 1 year high of $19.69. The firm has a fifty day moving average price of $4.04 and a 200-day moving average price of $4.09. The company has a market capitalization of $218.21 million, a price-to-earnings ratio of -1.48 and a beta of 2.81.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. As a group, analysts forecast that 4D Molecular Therapeutics will post -2.84 EPS for the current year.
Hedge Funds Weigh In On 4D Molecular Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BVF Inc. IL grew its position in 4D Molecular Therapeutics by 70.8% in the first quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock worth $14,733,000 after buying an additional 1,890,647 shares during the last quarter. Millennium Management LLC grew its position in 4D Molecular Therapeutics by 1,607.1% in the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock worth $7,913,000 after buying an additional 1,337,497 shares during the last quarter. Federated Hermes Inc. grew its position in 4D Molecular Therapeutics by 33,131.8% in the first quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock worth $4,038,000 after buying an additional 1,246,419 shares during the last quarter. JPMorgan Chase & Co. grew its position in 4D Molecular Therapeutics by 159.5% in the fourth quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock worth $4,568,000 after buying an additional 504,086 shares during the last quarter. Finally, Norges Bank acquired a new position in 4D Molecular Therapeutics in the fourth quarter worth approximately $2,790,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.
About 4D Molecular Therapeutics
(
Get Free Report4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
See Also
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access